Home › FDA grants orphan drug status to NBI-77860 for treatment of congenital adrenal hyperplasia
 

Keywords :   


FDA grants orphan drug status to NBI-77860 for treatment of congenital adrenal hyperplasia

2015-01-18 02:02:31| Biotech - Topix.net

Neurocrine Biosciences, Inc. announced today that NBI-77860, a proprietary corticotropin releasing factor 1 receptor antagonist, has been granted orphan drug status by the United States Food and Drug Administration for the treatment of congenital adrenal hyperplasia a disease that affects approximately 20,000-30,000 people in the United States. "We are very pleased that the FDA has granted NBI-77860 orphan status to treat congenital adrenal hyperplasia, a devastating disease that is a significant challenge for both clinicians and patients," said Malcolm Lloyd-Smith, Chief Regulatory Officer of Neurocrine Biosciences.

Tags: status treatment drug grants

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
23.06Atlantic Tropical Weather Outlook
23.06Eastern North Pacific Tropical Weather Outlook
22.06AI and agriculture: A look at whats ahead
22.06Atlantic Tropical Weather Outlook
22.06Atlantic Tropical Weather Outlook
22.06Eastern North Pacific Tropical Weather Outlook
22.06This Week in Agribusiness, June 22, 2024
22.06This Week in Agribusiness, June 22, 2024
More »